Skip to main content
SpringerLink
Log in

Allogeneic Stem Cell Transplantation

  • Chapter
  • First Online:
Multiple Myeloma

  • 2247 Accesses

Abstract

The survival of patients with multiple myeloma (MM) has improved over the past decade [1]. The most significant gains have been in patients without high-risk molecular markers. Despite these gains, multiple myeloma remains fatal and curative strategies are needed.

Allogeneic stem cell transplant (Allo-SCT) includes both myeloablative and nonmyeloablative or “reduced intensity conditioning” (RIC) transplants. Allogeneic transplant is appealing in theory because it avoids infusion of stem cells contaminated with myeloma cells and because there can be a beneficial graft vs. myeloma effect [2]. The role of Allo-SCT in myeloma, however, is debated due to the high mortality and morbidity. The high treatment-related mortality and significant toxicity from graft-versus-host disease (GVHD) have limited the role of this procedure in the treatment of myeloma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kumar SK, Rajkumar SV, Dispenzieri A, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111(5):2516–20.

    Article  CAS  PubMed  Google Scholar 

  2. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood. 2001;97(9):2574–9 [Erratum appears in Blood 2001 Jul 15;98(2):271; Blood 2001 Sep 15;98(6):1653].

    Article  CAS  PubMed  Google Scholar 

  3. Bensinger WI, Buckner CD, Anasetti C, et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome. Blood. 1996;88(7):2787–93.

    CAS  PubMed  Google Scholar 

  4. Gahrton G, Tura S, Ljungman P, et al. Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation. N Engl J Med. 1991;325(18):1267–73.

    Article  CAS  PubMed  Google Scholar 

  5. Gahrton G, Tura S, Ljungman P, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma [see comments]. J Clin Oncol. 1995;13(6):1312–22.

    CAS  PubMed  Google Scholar 

  6. Gahrton G, Svensson H, Cavo M, et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol. 2001;113(1):209–16.

    Article  CAS  PubMed  Google Scholar 

  7. Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol. 2006;24(6):929–36.

    Article  CAS  PubMed  Google Scholar 

  8. Lokhorst HM, Segeren CM, Verdonck LF, et al. Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM. J Clin Oncol. 2003;21(9):1728–33.

    Article  PubMed  Google Scholar 

  9. Bjorkstrand BB, Ljungman P, Svensson H, et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood. 1996;88(12):4711–8.

    CAS  PubMed  Google Scholar 

  10. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100(3):755–60.

    Article  CAS  PubMed  Google Scholar 

  11. Maloney DG, Molina AJ, Sahebi F, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood. 2003;102(9):3447–54.

    Article  CAS  PubMed  Google Scholar 

  12. Bjorkstrand B, Iacobelli S, Hegenbart U, et al. Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. J Clin Oncol. 2011;29(22):3016–22. Prepublished on 2011/07/07 as DOI JCO.2010.32.7312 [pii] 10.1200/JCO.2010.32.7312.

    Article  PubMed  Google Scholar 

  13. Bruno B, Rotta M, Patriarca F, et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med. 2007;356(11):1110–20.

    Article  CAS  PubMed  Google Scholar 

  14. Garban F, Attal M, Michallet M, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood. 2006;107(9):3474–80.

    Article  CAS  PubMed  Google Scholar 

  15. Giaccone L, Storer B, Patriarca F, et al. Long-term follow up of a comparison of non-myeloablative allografting with autografting for newly diagnosed myeloma. Blood. 2011;117(24):6721–7. Prepublished on 2011/04/15 as DOI blood-2011-03-339945 [pii] 10.1182/blood-2011-03-339945.

    Article  CAS  PubMed  Google Scholar 

  16. Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. Lancet Oncol. 2011;12(13):1195–203. doi:10.1016/s1470-2045(11)70243-1.

    Article  PubMed  Google Scholar 

  17. Rosinol L, Perez-Simon JA, Sureda A, et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood. 2008;112(9):3591–3. Prepublished on 2008/07/10 as DOI blood-2008-02-141598 [pii] 10.1182/blood-2008-02-141598.

    Article  CAS  PubMed  Google Scholar 

  18. Crawley C, Iacobelli S, Bjorkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood. 2007;109(8):3588–94.

    Article  CAS  PubMed  Google Scholar 

  19. Kumar S, Zhang MJ, Li P, et al. Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. Blood. 2011;118(7):1979–88. Prepublished on 2011/06/22 as DOI 10.1182/blood-2011-02-337329.

    Article  CAS  PubMed  Google Scholar 

  20. Osserman EF, DiRe LB, DiRe J, Sherman WH, Hersman JA, Storb R. Identical twin marrow transplantation in multiple myeloma. Acta Haematol. 1982;68(3):215–23.

    Article  CAS  PubMed  Google Scholar 

  21. Bensinger WI, Demirer T, Buckner CD, et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant. 1996;18(3):527–31. Prepublished on 1996/09/01 as DOI.

    CAS  PubMed  Google Scholar 

  22. Gahrton G, Svensson H, Bjorkstrand B, et al. Syngeneic transplantation in multiple myeloma—a case-matched comparison with autologous and allogeneic transplantation. European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1999;24(7):741–5. Prepublished on 1999/10/12 as DOI 10.1038/sj.bmt.1701975.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Mayo Clinic, 200 First Street, SW, Rochester, MN, 55905, USA

    Martha Q. Lacy M.D.

Authors
  1. Martha Q. Lacy M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martha Q. Lacy M.D. .

Editor information

Editors and Affiliations

  1. Mayo Clinic, Department of Internal Medicine Division of Hematology, Rochester, Minnesota, USA

    Morie A. Gertz

  2. Mayo Clinic, Myeloma Amyloidosis Dysproteinemia Group Division of Hematology, Rochester, Minnesota, USA

    S. Vincent Rajkumar

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Mayo Foundation for Medical Education and Research

About this chapter

Cite this chapter

Lacy, M.Q. (2014). Allogeneic Stem Cell Transplantation. In: Gertz, M., Rajkumar, S. (eds) Multiple Myeloma. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-8520-9_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-8520-9_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-8519-3

  • Online ISBN: 978-1-4614-8520-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation